Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $72.61
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 10, 26 |
Daily · Wilder smoothing
| Guggenheim |
| maintain |
| Buy |
| Buy |
| Aug 10, 26 | Canaccord Genuity | maintain | Hold | Hold |
| Jul 10, 26 | Guggenheim | maintain | Buy | Buy |
| Jan 16, 26 | Guggenheim | maintain | Buy | Buy |
| Nov 10, 25 | Guggenheim | maintain | Buy | Buy |
| Oct 9, 25 | Truist Securities | maintain | Hold | Hold |
| Sep 24, 25 | JP Morgan | maintain | Overweight | Overweight |
| Sep 17, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 8, 25 | Guggenheim | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.63 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 65.49 | Oscillator | Neutral |
| Williams %R (14) | -40.18 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.32 (Hist 0.17) | Oscillator | Buy |
| Average Directional Index (14) | 11.04 (+DI 14.7 / -DI 15.5) | Trend | Neutral |
| EMA 20 | 72.73 | MA | Sell |
| SMA 20 | 72.51 | MA | Buy |
| EMA 50 | 73.93 | MA | Sell |
| SMA 50 | 73.44 | MA | Sell |
| SMA 200 | 77.89 | MA | Strong Sell |
Stock news · updated daily
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00. Following the completion of the transaction, the chief executive officer owned 333,689
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 7, 2026 | 2.04 | 2.21 | Beat 8.3% | $266.0M |
| May 8, 2026 | 1.28 | 2.05 | Beat 60.2% | $237.5M |
| Feb 27, 2026 | 1.99 | 2.33 | Beat 17.1% | $247.1M |
| Nov 7, 2025 | 1.74 | 2.04 | Beat 17.2% | $227.8M |
| Aug 8, 2025 | 1.38 | 1.80 | Beat 30.4% | $211.4M |
| May 9, 2025 | 1.37 | 1.70 | Beat 24.1% | $197.1M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ANIP | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 15.0x | 0.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 7.8x | EPS est. 9.26 | Discount |
| Price / Book | 2.6x | 2.2x | Elevated |
| Price / Sales | 1.7x | 2.1x | Discount |
| EV / EBITDA | 6.4x | 64.8x | Discount |
| Return on equity | 19.2% | — | Healthy |
| Gross margin | 65.2% | 56.5% | Above hist. |
| Debt / Equity | 0.55 | 0.87 | Moderate |
| Piotroski / Altman Z | 7/9 | Z 2.63 | Grey zone |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 16, 2026 | 2026-10-16 18:50:07 | View |
| 4 | Oct 13, 2026 | 2026-10-13 20:47:42 | View |
| 4 | Sep 30, 2026 | 2026-09-30 16:52:15 | View |
| 4 | Sep 16, 2026 | 2026-09-16 16:20:52 | View |
| 4 | Sep 14, 2026 | 2026-09-14 20:57:19 | View |
| 4 | Sep 14, 2026 | 2026-09-14 20:56:53 | View |
| 4 | Sep 1, 2026 | 2026-09-01 18:18:41 | View |
| 4 | Aug 27, 2026 | 2026-08-27 16:21:57 | View |
| 3 | Aug 27, 2026 | 2026-08-27 16:20:02 | View |
| 4 | Aug 26, 2026 | 2026-08-26 18:15:10 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | S-Sale | 5,400 @ $71.89 | $388.2K |
| Oct 13, 26 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | S-Sale | 500 @ $73.59 | $36.80K |
| Sep 29, 26 | Carey Stephen P. | officer: SVP & CFO | S-Sale | 2,850 @ $73.00 | $208.1K |
| Sep 15, 26 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | S-Sale | 5,400 @ $71.00 | $383.4K |
| Sep 11, 26 | Thoma Jeanne | director | S-Sale | 1,000 @ $71.53 | $71.53K |
| Sep 14, 26 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | S-Sale | 500 @ $70.79 | $35.40K |
| Aug 31, 26 | Carey Stephen P. | officer: SVP & CFO | S-Sale | 2,850 @ $72.80 | $207.5K |
| Aug 19, 26 | Gosebruch Henry O | director | A-Award | 6,662 | — |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure